GlassScriptPhysician profile
Montgomery L Roberts
NPI 1124089321
$3,616.88
in general payments reported to CMS, 2019-2025
30 companies · $496 in 2025
The $496 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $336 · 2021: $364 · 2022: $403 · 2023: $628 · 2024: $483 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $671.42 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $587.01 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $421.62 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $255.15 | 2019-2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $245.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.97 | 2019-2025 | Ofev |
| Insmed, INC. | $204.08 | 2019-2025 | Arikayce |
| Grifols USA, LLC | $165.15 | 2019-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $93.41 | 2019-2025 | Zerbaxa, Recarbrio |
| Baxter Healthcare | $63.28 | 2023 | Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $60.47 | 2023 | |
| Lilly USA, LLC | $57.14 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $55.38 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $50.18 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Pulmonx Corporation | $49.29 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $49.23 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $47.39 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $41.93 | 2022-2023 | Acthar |
| Advanced Respiratory, INC | $33.55 | 2020 | |
| Amgen INC. | $33.33 | 2023-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $29.31 | 2024 | Entyvio |
| Vapotherm INC | $25.39 | 2020 | |
| Philips North America LLC | $24.30 | 2025 | Encore |
| Galvanize Therapeutics, INC | $23.60 | 2023 | Aliya System |
| Gilead Sciences, INC. | $22.38 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.85 | 2020 | |
| Viatris Specialty LLC | $16.58 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $16.44 | 2021 | |
| Verona Pharma, INC. | $15.61 | 2025 | Ohtuvayre |
| Circassia INC. | $15.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Montgomery Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.